1. Volume 15, Issue 1, Pages 78-86 (January 2014)
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial 
Dr Hugo E R Ford, MD, Andrea Marshall, PhD, John A Bridgewater, PhD, Tobias Janowitz, PhD, Fareeda Y Coxon, MRCP, Jonathan Wadsley, FRCR, Wasat Mansoor, PhD, David Fyfe, MD, Srinivasan Madhusudan, FRCP, Prof Gary W Middleton, MD, Daniel Swinson, MD, Stephen Falk, MD, Ian Chau, MD, Prof David Cunningham, MD, Paula Kareclas, PhD, Natalie Cook, PhD, Prof Jane M Blazeby, MD, Prof Janet A Dunn, PhD 
The Lancet Oncology 
Volume 15, Issue 1, Pages (January 2014)
DOI: /S (13)
Copyright © 2014 Ford et al. Open Access article distributed under the terms of CC BY Terms and Conditions

2. Figure 1
Trial profile
The Lancet Oncology  , 78-86DOI: ( /S (13) )
Copyright © 2014 Ford et al. Open Access article distributed under the terms of CC BY Terms and Conditions

3. Figure 2 Kaplan-Meier plot of overall survival
The Lancet Oncology  , 78-86DOI: ( /S (13) )
Copyright © 2014 Ford et al. Open Access article distributed under the terms of CC BY Terms and Conditions

4. Figure 3
Hazard ratio plot of the treatment effect by prognostic factors for overall survival
ECOG PS=Eastern Cooperative Oncology Group performance status.
The Lancet Oncology  , 78-86DOI: ( /S (13) )
Copyright © 2014 Ford et al. Open Access article distributed under the terms of CC BY Terms and Conditions

5. Figure 4 Health-related quality of life (HRQL) outcomes.
Positive values in function scale and negative values for the symptom scale denote benefit from docetaxel compared with active symptom control.
The Lancet Oncology  , 78-86DOI: ( /S (13) )
Copyright © 2014 Ford et al. Open Access article distributed under the terms of CC BY Terms and Conditions